Array BioPharma, Inc. (NASDAQ:ARRY)

CAPS Rating: 4 out of 5

A biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat life threatening and debilitating diseases.

Recs

1
Player Avatar cashsage (29.56) Submitted: 12/7/2009 3:27:21 PM : Underperform Start Price: $2.09 ARRY Score: +9.01

ARRY has a too high valuation compared to its sales potential. It is also one of the most loss making companies. It may go bankrupt.

Featured Broker Partners


Advertisement